Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangdong
Clinical trial register · China

Clinical Trials in Guangdong, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University9 Second Affiliated Hospital, Zhejiang University, School of Medicine3 Takeda3 AstraZeneca3 Eli Lilly and Company3 Zhongshan Ophthalmic Center, Sun Yat-sen University3 Allist Pharmaceuticals, Inc.2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2 Jie Yuan，MD2 Fudan University2 RemeGen Co., Ltd.2 Sichuan Baili Pharmaceutical Co., Ltd.2 Daiichi Sankyo2 Chinese PLA General Hospital1 Shanghai Zhongshan Hospital1 Albireo, an Ipsen Company1 Beijing InnoCare Pharma Tech Co., Ltd.1 Abbisko Therapeutics Co, Ltd1 Xuanwu Hospital, Beijing1 Huabo Biopharm Co., Ltd.1 RenJi Hospital1 Peking University Shenzhen Hospital1 Zhou Chengzhi1 Shanghai Pushi Medical Science Co. Ltd1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1 Show all 51
Site location
Beijing5606 Shanghai3892 Guangzhou3359 Hangzhou1833 Wuhan1342 Chengdu1310 Nanjing1216 Changsha1159 Chongqing1085 Fuzhou1041 Tianjin940 Zhengzhou926 Hefei909 Jinan794 Changchun642 Shenzhen585 Harbin549 Nanchang449 Nanning443 Xi'an443 Suzhou433 Shenyang406 Xiamen391 Shijiazhuang351 Lanzhou273 Show all 625
All 625 locations
Target enrolment
to

Trials with a site in Guangdong

76 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
RemeGen Co., Ltd.
Phase 2
412
Guangdong
2026-11
Recruiting
Takeda
Phase 2
36
Beijing, Guangdong, Nanning, Wuhan, Xi'an, Jinan, Chengdu, Hangzhou
2026-10-27
Recruiting
Jie Yuan，MD
Observational
15
Guangdong
2026-09-09
Recruiting
Jie Yuan，MD
Observational
30
Guangdong
2026-09-01
Not yet open
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
NCT07746453IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Guangdong Provincial People's Hospital
Not applicable
24
Guangdong
2026-08-31
Recruiting
Xinyu ZHANG
Not applicable
106
Guangdong
2026-08-10
Not yet open
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
1,000
Guangdong
2026-08-01
Not yet open
Sun Yat-sen University
Phase 2
347
Guangdong
2026-07-07
Not yet open
Chinese PLA General Hospital
Early Phase 1
250
Guangdong, Beijing
2026-06-01
Recruiting
Sun Yat-sen University
Phase 2
57
Guangdong
2026-06-01
Recruiting
RemeGen Co., Ltd.
Phase 1/2
326
Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing
2026-04-27
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
Beijing Tiantan Hospital
Not applicable
376
Dongguan, Guangdong, Zhengzhou, Jinan, Jining, Ningbo, Beijing
2026-03-13
Recruiting
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Not yet open
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
54
Guangdong
2026-02-28
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
DrugMontelukast
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Ha’erbin, Hefei, Hunan, Shenyang
2026-02-01
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
20
Guangdong
2026-01-16
Not yet open
Sun Yat-sen University
Not applicable
252
Guangdong
2026-01
Not yet open
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
54
Guangdong
2025-12-25
Active, closed
Sun Yat-sen University
Phase 2
62
Guangdong
2025-12-17
Recruiting
Rui You
Phase 2
22
Guangdong
2025-12-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
600
Guangdong, Guangzhou
2025-12-01
Recruiting
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Sun Yat-sen University
Phase 2
41
Guangdong
2025-10-17
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou
2025-07-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
AstraZeneca
Observational
700
Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou, Hangzhou
2025-07-11
By invitation
Peking University Shenzhen Hospital
Not applicable
100
Guangdong
2025-07-03
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
338
Beijing, Guangdong
2025-05-28
Recruiting
Takeda
Phase 2
192
Chongqing, Guangdong, Guangzhou, Shanghai
2025-05-28
Recruiting
Sun Yat-sen University
Not applicable
24
Guangdong
2025-04-10
Recruiting
Tubeless Tracheal and Carinal Reconstruction
NCT07065565Tracheal Disease, Airway Disease
Shuben Li
Not applicable
176
Guangdong
2025-03-26
Recruiting
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
380
Guangdong
2024-09-26
Active, closed
Zhou Chengzhi
Observational
100,000
Guangdong
2024-09-05
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1
Guangdong
2024-07-12
Recruiting
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
A Study of HLX42 in Advanced/Metastatic Solid Tumors
NCT06210815Solid Tumor and NSCLC
Shanghai Henlius Biotech
Phase 1
102
Guangdong
2024-03-14
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Active, closed
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Sun Yat-sen University
Phase 3
126
Guangdong
2023-06-10
Recruiting
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an
2023-01-12
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Beijing, Fujian, Guangdong, Henan, Hubei, Shanxi, Shengyang, Tianjin
2022-12-07
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Active, closed
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
Sun Yat-sen University
Not applicable
124
Guangzhou, Guangdong
2021-05-31
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou, Beijing, Chongqing, Fujian, Gansu, Guangdong, Guangxi, Guizhou
2020-07-08
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Active, closed
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Rows per page Showing 1–76 of 76
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangdong

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 15 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 76 of those studies with a site in Guangdong.

How many clinical trials are recruiting in Guangdong?

49 of the 76 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:17 UTC sync. A further 9 have not yet opened recruitment, 16 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangdong), 76 studies
PhaseStudiesRecruitingShare
Phase 3181323.7%
Not applicable16821.1%
Phase 216821.1%
Observational12815.8%
Phase 1779.2%
Phase 1/2333.9%
Phase 4222.6%
Early Phase 1101.3%
Phase 2/3101.3%

Most active sponsors

Lead sponsors with the most studies (Guangdong)
Lead sponsorStudiesRecruiting
Sun Yat-sen University95
AstraZeneca31
Eli Lilly and Company33
Second Affiliated Hospital, Zhejiang University, School of Medicine31
Takeda33
Zhongshan Ophthalmic Center, Sun Yat-sen University30
Allist Pharmaceuticals, Inc.22
Daiichi Sankyo21
Fudan University22
Jie Yuan，MD22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.